🧬 biology

Evidence for Reactivation of Embryonic Cytoskeletal Remodeling Programs, silenced decades earlier, in Amyotrophic Lateral Sclerosis

This study demonstrates that amyotrophic lateral sclerosis (ALS) is characterized by the coordinated reactivation of embryonic cytoskeletal remodeling programs, specifically involving upregulated Arp2/3-mediated actin dynamics, MYH10-associated contractility, and developmental glial pathways, suggesting these silenced mechanisms are key to disease pathogenesis and potential therapeutic targets.

Original authors: Steven Lehrer

Published 2026-08-14

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Steven Lehrer

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body is a bustling city, and inside every cell, there's a complex network of roads, bridges, and construction crews. These "roads" are made of tiny protein strands called the cytoskeleton. In a grown-up city (a mature adult body), these roads are stable, paved, and designed for long-distance traffic to keep everything running smoothly. But when a city is first being built (during embryonic development), the construction crews are wild, creative, and constantly tearing things down to build new bridges and move buildings around. They use special tools to branch out and pull with great force to shape the city.

Now, imagine a disease called Amyotrophic Lateral Sclerosis (ALS). This is a condition where the nerve cells that control your muscles slowly break down, leading to paralysis. Scientists have long wondered why this happens. They know many things go wrong, like trash piling up or power plants failing, but they haven't found the one big "master switch" that explains the whole mess. A fascinating idea has popped up: What if, instead of just breaking down, the adult nerve cells accidentally wake up the "construction crew" from their childhood? What if they start trying to rebuild their roads like they did when they were babies, even though they are fully grown? This paper dives into that exact question, looking for evidence that the "baby construction tools" are being turned on in the brains of people with ALS.

The Paper: Waking Up the Baby Construction Crew

In this study, researcher Steven Lehrer decided to investigate whether ALS is actually a case of "developmental amnesia," where the brain forgets to stay mature and reactivits the chaotic, energetic construction programs it used during embryonic development. To do this, he didn't look at living people; instead, he analyzed a massive digital library of genetic instructions (RNA-sequencing data) taken from the brains and spinal cords of 310 people who had ALS and 72 people who did not, courtesy of the Target ALS Postmortem Tissue Core.

Think of the cytoskeleton as a tug-of-war team. On one side, you have the Arp2/3 complex, which acts like a branching machine, sprouting new protein strands to push the cell forward (like a construction crew pushing a wall). On the other side, you have MYH10, a muscle-like protein that acts as a winch, pulling everything tight to create tension. In a healthy adult, these two are quiet and balanced. But the paper suggests that in ALS, the cell is trying to run a "reconstruction project" it doesn't need.

What the Data Showed
When Lehrer ran the numbers, he found a loud, coordinated signal that the "baby construction" was indeed waking up. The data revealed that in people with ALS:

The Arp2/3 complex was significantly louder, with a statistical score showing a strong increase (β = 0.399, P = 8.26×10⁻⁹).
The MYH10 winch was also revving up (β = 0.308, P = 0.000801).
Genes that usually only work in baby brains to build glial cells (the support crew of the nervous system), specifically SOX9 and MEGF10, were also shouting much louder (β = 0.643, P = 4.28×10⁻⁶).
There was also a mismatch in the transport system: the "winch" (MYH10) was getting stronger relative to the "delivery truck" (KIF5C), suggesting the cell was prioritizing remodeling over moving supplies (β = 0.121, P = 0.00537).

The Twist: It's a Team Effort, Not a Solo Act
Here is where the story gets really interesting. The researchers wanted to know: Is the winch (MYH10) the boss, or is the branching machine (Arp2/3) the boss? They ran a special test to see which one was driving the other.

The results suggested that the Arp2/3 complex is the main driver. When they accounted for the Arp2/3 activity, the link between ALS and MYH10 disappeared, meaning MYH10 was just following orders. However, even after accounting for MYH10, the Arp2/3 complex was still strongly linked to ALS. It's as if the Arp2/3 complex is the foreman shouting, "Let's rebuild!" and the MYH10 winch is just the worker picking up a tool because it was told to.

What Was Ruled Out
The paper also checked a specific idea: that the cell was just pulling too hard without building anything new. They calculated a "contractility index" to see if the pulling force (MYH10) was out of sync with the branching (Arp2/3). The result? Nothing. The index was not significant (P = 0.107). This means the cell isn't just randomly pulling; the pulling and the branching are happening together, in perfect, coordinated rhythm, just like they do in a developing embryo.

How Sure Are We?
The author is confident that these patterns exist in the genetic data they analyzed. They found that four out of five specific measurements they looked at were statistically significant, even after correcting for the fact that they were testing many things at once. However, they are careful to note that this is a "snapshot" taken after death. They can see the construction crew is awake, but they can't prove when it woke up or if it caused the disease or if it's just a reaction to it. They also note that seeing the genetic instructions (RNA) doesn't guarantee the actual tools (proteins) are fully built and working, though the evidence is very strong.

The Bottom Line
This paper suggests that ALS isn't just a random breakdown of parts. Instead, it looks like a coordinated, albeit alternative, attempt by adult nerve cells to reactivate their embryonic "construction mode." The Arp2/3 complex seems to be the master switch turning this mode on, dragging the MYH10 winch and other developmental genes along for the ride. While this doesn't solve the mystery of ALS yet, it points scientists toward a new direction: maybe the cure isn't just fixing one broken part, but figuring out how to gently tell the cell, "You're grown up now, please go back to sleep."

Technical Summary: Reactivation of Embryonic Cytoskeletal Remodeling Programs in ALS

Problem Statement
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the selective loss of motor neurons. While numerous molecular abnormalities have been identified—including protein aggregation, RNA dysregulation, mitochondrial dysfunction, and neuroinflammation—no unifying mechanism explains how these diverse processes integrate during disease progression. A prevailing hypothesis suggests that neurodegeneration may involve the inappropriate reactivation of embryonic developmental programs, specifically those governing neuronal morphogenesis, actin polymerization, and cytoskeletal dynamics. These programs, which drive growth cone migration and neurite extension during development, are typically silenced in mature neurons. The study investigates whether ALS is characterized by a coordinated reactivation of these embryonic cytoskeletal remodeling pathways, specifically focusing on the Arp2/3 complex, non-muscle myosin IIB (MYH10), and developmental glial regulators.

Methodology
The study utilized a retrospective, cross-sectional design analyzing postmortem RNA-sequencing data from the Target ALS Postmortem Tissue Core.

Cohort: The analytic cohort was restricted to 382 subjects (310 ALS patients and 72 non-neurological controls). Subjects with compound or alternative neurological diagnoses (e.g., ALS-FTD) were excluded.
Data Structure: The dataset included 1,674 tissue-sample observations from 360 subjects, with multiple samples per donor.
Statistical Approach: Linear mixed-effects models were employed to account for repeated tissue samples within individual subjects using subject-specific random intercepts. Models were adjusted for tissue source, age at death, sex, and postmortem interval (PMI).
Composite Scores: To evaluate coordinated biological programs rather than isolated gene expression, the author calculated composite pathway scores:
- Arp2/3 Score: Mean log2(TPM + 1) expression of nine Arp2/3 complex genes (ACTR2, ACTR3, ARPC1A–E, ARPC5, ARPC5L).
- Developmental-Glial Score: Mean expression of SOX9 and MEGF10.
- Transport Mismatch Index: Difference between MYH10 and KIF5C expression.
- Contractility Index: Difference between MYH10 and the Arp2/3 score.
Reciprocal Modeling: To determine the independence of pathways, reciprocal models were fitted to test whether MYH10 activation is an independent abnormality or part of a broader Arp2/3-centered program.
Correction: Multiple comparisons were controlled using the Benjamini-Hochberg false discovery rate (FDR) procedure.

Key Results
The analysis revealed robust, coordinated activation of embryonic cytoskeletal and glial pathways in ALS tissue compared to controls:

Arp2/3 Pathway: ALS was significantly associated with increased Arp2/3 expression ( $\beta = 0.399$ , $P = 8.26 \times 10^{-9}$ , FDR-adjusted $P = 4.13 \times 10^{-8}$ ).
Developmental Glial Genes: Significant upregulation of the SOX9/MEGF10 score was observed ( $\beta = 0.643$ , $P = 4.28 \times 10^{-6}$ , FDR-adjusted $P = 1.07 \times 10^{-5}$ ).
MYH10 Expression: MYH10 expression was significantly elevated ( $\beta = 0.308$ , $P = 0.000801$ , FDR-adjusted $P = 0.00134$ ).
Transport Imbalance: The MYH10–KIF5C transport mismatch index was significantly increased ( $\beta = 0.121$ , $P = 0.00537$ , FDR-adjusted $P = 0.00671$ ), suggesting a shift toward contractility over axonal transport.
Contractility Index: The MYH10–Arp2/3 contractility index was not significantly associated with ALS ( $P = 0.107$ ), indicating that MYH10 and Arp2/3 increase in tandem rather than one disproportionately.

Reciprocal Modeling Findings
Reciprocal mixed-effects modeling provided insight into the hierarchy of these pathways:

MYH10 expression was tightly coupled to Arp2/3 pathway activity.
When adjusting for MYH10 expression, the ALS diagnosis remained independently associated with increased Arp2/3 activity.
Conversely, when adjusting for Arp2/3 activity, the ALS diagnosis was no longer independently associated with MYH10 expression.
This asymmetry suggests that MYH10 upregulation occurs largely within a broader Arp2/3-centered remodeling program, whereas Arp2/3 signaling captures additional disease-associated biology independent of MYH10.

Significance and Claims
The paper claims that these findings support the hypothesis that ALS is characterized by the coordinated reactivation of embryonic cytoskeletal remodeling programs rather than the isolated dysregulation of individual structural proteins.

Mechanistic Insight: The data suggest that the disease involves a partial re-engagement of developmental machinery, where branched actin polymerization (Arp2/3) and actomyosin contractility (MYH10) are reactivated together.
Glial Involvement: The activation of SOX9 and MEGF10 indicates that these developmental programs extend beyond neurons to glial populations.
Therapeutic Implication: The author posits that targeting individual downstream proteins (like MYH10) may be less effective than modulating upstream regulators of the coordinated remodeling program, such as the Arp2/3 complex, which appears to be a central driver.

Limitations Acknowledged by the Authors
The author explicitly notes several constraints:

Cross-sectional Nature: The use of postmortem tissue prevents establishing the temporal sequence of events (i.e., whether reactivation initiates disease or is a secondary response).
Transcriptomic vs. Functional: Gene expression does not necessarily reflect protein abundance or functional activity; proteomic and histological validation is required.
Bulk Tissue Resolution: Bulk RNA-sequencing cannot resolve which specific neuronal or glial subpopulations drive the observed changes.
Causality: The interpretation of "reactivation" is a biologically plausible framework, but functional experimental studies are needed to establish causality.

In conclusion, the study identifies Arp2/3-centered actin remodeling as a major molecular feature of ALS, providing a unified framework for understanding cytoskeletal dysregulation in the disease.

The Paper: Waking Up the Baby Construction Crew

Technical Summary: Reactivation of Embryonic Cytoskeletal Remodeling Programs in ALS

More like this